The Danish drugmaker sued Hims in February over compounded versions of the Wegovy weight-loss pill that Hims launched and ...

Novo dropped its patent-infringement case against telehealth provider Hims & Hers after the companies agreed that Hims would ...

By Stine Jacobsen and Maggie Fick COPENHAGEN, March 9 (Reuters) - Novo Nordisk has agreed to sell its blockbuster Wegovy and Ozempic drugs through U.S. telehealth company Hims & Hers' platform, the ...

Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers, as the two companies have ...

Hims & Hers shares jumped more than 50% in premarket trade on Monday after ending a dispute with Novo Nordisk by striking a ...

Once used exclusively for managing diabetes, celebrities' use of weight loss medications like Ozempic, Mounjaro, Wegovy, ...

A recent small study has found that people may be able to maintain their weight loss with fewer GLP-1 injections, but this ...

Eye strokes’ that reduce blood flow to optic nerve likely to be side-effect of active ingredient semaglutide, says author ...

Wegovy is a Food and Drug Administration-approved weight loss medication for people with obesity or those who are overweight with weight-related health conditions. In recent years, interest in ...

Weight loss jab ‘may carry higher risk of sudden sight loss’ as new warning issued - Wegovy is approved on the NHS to help people lose weight in higher doses ...

Share on Pinterest Researchers believe that high doses of semaglutide may reduce blood flow to the optic nerve, which could lead to eye stroke. Maria Korneeva/Getty Images A new study has found that ...

Citi stays 'neutral' on Novo Nordisk as crowded obesity market threatens to erode its competitive edge Novo Nordisk (NYSE:NVO), the Danish pharma giant behind the Ozempic and Wegovy weight-loss drugs, ...